Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 7,76€(+97,96%). Der Median liegt bei 7,76€(+97,96%).
Kaufen | 3 |
Halten | 3 |
Verkaufen | 1 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Evotec: Some Recovery Has Come, But Much More Is Expected
Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside.» Mehr auf seekingalpha.com
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai.» Mehr auf accesswire.com
Evotec Announces Change in Management Board
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024 Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS.» Mehr auf accesswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Sep. 2024 | |
---|---|---|
Umsatz | 184,89 Mio | 5,80% |
Bruttoeinkommen | 18,28 Mio | 51,66% |
Nettoeinkommen | −39,63 Mio | 1,74% |
EBITDA | −45,01 Mio | 361,57% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 1,41 Mrd€ |
Anzahl Aktien | 354,61 Mio |
52 Wochen-Hoch/Tief | 8,13€ - 2,76€ |
Dividenden | Nein |
Beta | 0,98 |
KGV (PE Ratio) | −8,27 |
KGWV (PEG Ratio) | −0,08 |
KBV (PB Ratio) | 1,46 |
KUV (PS Ratio) | 1,82 |
Unternehmensprofil
Evotec SE ist als Wirkstoffforschungs- und -entwicklungspartner für die Pharma- und Biotechnologiebranche weltweit tätig. Das Unternehmen entwickelt pharmazeutische Produkte in verschiedenen therapeutischen Bereichen wie Diabetes und Diabetes-Komplikationen, Fibrose, Infektionskrankheiten, ZNS-Erkrankungen, Onkologie, Schmerz und Entzündung, Immunologie, seltene Krankheiten, Atemwegserkrankungen und Frauengesundheit. Das Unternehmen hat Kooperationsvereinbarungen mit Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd, Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics und Takeda Pharmaceuticals. Das Unternehmen war früher unter dem Namen Evotec AG bekannt und änderte im April 2019 seinen Namen in Evotec SE. Evotec SE wurde 1993 gegründet und hat seinen Hauptsitz in Hamburg, Deutschland.
Name | Evotec ADR |
CEO | Dr. Christian Wojczewski |
Sitz | Hamburg, Deutschland |
Website | |
Industrie | Chemikalien |
Börsengang | 05.02.2004 |
Mitarbeiter | 5.007 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | EVO |
Frankfurt | EVTA.F |
Düsseldorf | EVTA.DU |
München | EVTA.MU |
Assets entdecken
Shareholder von Evotec ADR investieren auch in folgende Assets